Epigenetic regulators combined with tumour immunotherapy: current status and perspectives DOI Creative Commons
Huan Zhang, Yuepeng Pang, Ling Yi

et al.

Clinical Epigenetics, Journal Year: 2025, Volume and Issue: 17(1)

Published: March 21, 2025

Immunotherapy, particularly immune checkpoint inhibitor therapy, has demonstrated clinical benefits in solid tumours. Despite its satisfactory efficacy, it still faces several issues, such as limited eligibility, low response rates and cytotoxicity. Cancer epigenetics implies that tumour cells exhibit unique phenotypes because of their characteristics, thus reprogramming the epigenome holds promise for cancer therapy. Epigenetic regulation plays an important role regulating gene expression during development maintenance. regulators induce cell cycle arrest, apoptosis differentiation cells, thereby exerting anti-tumour effects. Recent studies have revealed a significant correlation between epigenetic regulatory factors Epigenetics can modulate various aspects microenvironment to enhance sensitivity immunotherapy, lowering concentration required mitigating This review primarily discusses DNA methyltransferase inhibitors, histone deacetylase enhancer zeste homolog 2 inhibitors lysine-specific demethylase 1 which are associated with transcriptional repression. repression alters genes involved checkpoint, enhancing effectiveness immunotherapy. We also discuss potential challenges immunotherapy highlight advantages, application research on integrating

Language: Английский

Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands DOI Creative Commons
Alí N. Kamali, José M. Bautista, Michael Eisenhut

et al.

Therapeutic Advances in Vaccines and Immunotherapy, Journal Year: 2023, Volume and Issue: 11

Published: Jan. 1, 2023

Checkpoint markers and immune checkpoint inhibitors have been increasingly identified developed as potential immunotherapeutic targets in various human cancers. Despite valuable efforts to discover novel checkpoints their ligands, the precise roles of therapeutic functions, well broad identification counterpart receptors, remain be addressed. In this context, it has suggested that putative receptors can induced upon activation. tumor microenvironment, T cells, crucial response against malignant diseases other central effector such natural killer are regulated via co-stimulatory or co-inhibitory signals from cells. Studies shown exposure cells antigens upregulates expression inhibitory leading T-cell dysfunction exhaustion. Although targeting regulators relative clinical efficacy some types, most trials field cancer immunotherapies revealed unsatisfactory results due de novo adaptive resistance patients. To overcome these obstacles, combinational therapies with newly discovered molecules combined blockage several provide a rationale for further research. Moreover, counterparts at is likely promise effective therapies. review, we examine prospects application emerging checkpoints, immunoglobulin mucin domain 3, lymphocyte activation gene-3, immunoreceptor Ig ITIM domains (TIGIT), V-domain suppressor (VISTA), new B7 family proteins, B- attenuator, association immunotherapy malignancies. addition, biological significance discussed, including cancers, along T-cell-mediated responses.

Language: Английский

Citations

21
BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia DOI Open Access
Christian Sordo‐Bahamonde, Seila Lorenzo‐Herrero, Ana Pilar González-Rodríguez

et al.

Cancers, Journal Year: 2021, Volume and Issue: 13(8), P. 1766 - 1766

Published: April 7, 2021

Chronic lymphocytic leukemia (CLL) is characterized by progressive immunosuppression and diminished cancer immunosurveillance. Immune checkpoint blockade (ICB)-based therapies, a major breakthrough against cancer, have emerged as powerful tool to reinvigorate antitumor responses. Herein, we analyzed the role of novel inhibitory BTLA its ligand, HVEM, in regulation leukemic natural killer (NK) cells CLL. Flow cytometry analyses showed that expression upregulated on NK from patients with CLL, whereas HVEM downregulated only cells, especially advanced Rai-Binet stage. In silico analysis revealed increased but not BTLA, mRNA correlated overall survival. Further, soluble (sBTLA) was found be sera CLL highly poor prognostic markers shorter time treatment. an anti-BTLA monoclonal antibody depleted boosted cell-mediated responses ex vivo increasing their IFN-γ production, cytotoxic capability, antibody-dependent cytotoxicity (ADCC). agreement surface associated outcome Overall, this study first bring light BTLA/HVEM suppression immune impact patient’s prognosis, suggesting axis may potential therapeutic target disease.

Language: Английский

Citations

37
Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside DOI
Farid Ghorbaninezhad, Zahra Asadzadeh, Javad Masoumi

et al.

Life Sciences, Journal Year: 2022, Volume and Issue: 297, P. 120466 - 120466

Published: March 7, 2022

Language: Английский

Citations

26
5-Methylcytosine Related LncRNAs Reveal Immune Characteristics, Predict Prognosis and Oncology Treatment Outcome in Lower-Grade Gliomas DOI Creative Commons
Jiheng Zhang, Nan Wang, Jiasheng Wu

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: March 3, 2022

5-Methylcytosine (m5C) methylation is an important RNA modification pattern that can participate in oncogenesis and progression of cancers by affecting stability, expression oncogenes, the activity cancer signaling pathways. Alterations long non-coding RNAs (lncRNAs) are potentially correlated with abnormalities m5C regulation features cancers. Our aim was to reveal mechanisms which lncRNAs regulated process, explore impact aberrant on biological properties lower-grade gliomas (LGG), optimize current therapeutic. By searching 1017 LGG samples from Cancer Genome Atlas Chinese Glioma Atlas, we first clarified potential regulators prognosis this study used univariate Cox analysis least absolute shrinkage selection operator regression clinically meaningful lncRNAs. Consequently, identified four lncRNAs, including LINC00265, CIRBP-AS1, GDNF-AS1, ZBTB20-AS4, established a novel m5C-related signature (m5CrLS) effective predicting prognosis. Notably, mutation rate, WHO class II, IDH mutation, 1p/19q co-deletion MGMT promoter were increased low m5CrLS score group. Patients scores mostly showed activation tumor malignancy-related pathways, immune infiltrating cells, decreased anti-tumor function. Besides, relatively high checkpoints also revealed immunosuppressed state patients scores. In particular, stratification sensitive assess efficacy temozolomide responsiveness checkpoint blockade. conclusion, our results molecular basis LGG, provided valuable clues for understanding filled gap between epigenetics microenvironment.

Language: Английский

Citations

25
Inhibitory Immune Checkpoint Receptors and Ligands as Prognostic Biomarkers in COVID-19 Patients DOI Creative Commons
Mohammad A. Al-Mterin,

Alhasan Alsalman,

Eyad Elkord

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: March 31, 2022

Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2. During T-cell activation, the immune system uses different checkpoint pathways to maintain co-inhibitory and co-stimulatory signals. In COVID-19, expression of checkpoints (ICs) one most important manifestations, in addition lymphopenia inflammatory cytokines, contributing worse clinical outcomes. There a controversy whether upregulation ICs COVID-19 patients might lead exhaustion or activation. This review summarizes available studies that investigated IC receptors ligands patients, as well their effect on function. Several ligands, including CTLA-4, BTLA, TIM-3, VISTA, LAG-3, TIGIT, PD-1, CD160, 2B4, NKG2A, Galectin-9, Galectin-3, PD-L1, PD-L2, LSECtin, CD112, were upregulated patients. Based studies, there possible relationship between severity increased ligands. Overall, some could be used prognostic biomarker for severity.

Language: Английский

Citations

24
Recent advances in immunotherapy in cancer treatment DOI Creative Commons
Ayyub Patel

Cellular and Molecular Biology, Journal Year: 2024, Volume and Issue: 70(5), P. 89 - 99

Published: May 27, 2024

Language: Английский

Citations

6
The Dual Role of B Cells in the Tumor Microenvironment: Implications for Cancer Immunology and Therapy DOI Open Access
Hao Yang,

Zhiru Zhang,

Jijun Li

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(21), P. 11825 - 11825

Published: Nov. 4, 2024

The tumor microenvironment (TME) is a complex and heterogeneous tissue composed of various cell types, including cells, stromal immune as well non-cellular elements. Given their pivotal role in humoral immunity, B cells have emerged promising targets for anti-tumor therapies. dual nature exhibiting both tumor-suppressive tumor-promoting functions, has garnered significant attention. Understanding the distinct effects subsets on different tumors could pave way novel targeted This review provides comprehensive overview multifaceted roles tumorigenesis, therapeutic potential targeting cancer treatment. To develop more effective immunotherapies, it essential to decipher heterogeneity shaping TME.

Language: Английский

Citations

6
Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy DOI

Shunyao Zhu,

Xixi Li, Ziyi Luo

et al.

Drug Delivery and Translational Research, Journal Year: 2023, Volume and Issue: 14(3), P. 718 - 729

Published: Sept. 7, 2023

Language: Английский

Citations

12
B‐cell performance in chemotherapy: Unravelling the mystery of B‐cell therapeutic potential DOI Creative Commons
Zizhuo Li, Anqi Lin, Zhifei Gao

et al.

Clinical and Translational Medicine, Journal Year: 2024, Volume and Issue: 14(7)

Published: July 1, 2024

Abstract Background and main body The anti‐tumour tumour‐promoting roles of B cells in the tumour microenvironment (TME) have gained considerable attention recent years. As essential orchestrators humoral immunity, potentially play a crucial role therapies. Chemotherapy, mainstay cancer treatment, influences proliferation function diverse B‐cell subsets their crosstalk with TME. Modulating by targeting or associated may enhance chemotherapy efficacy, presenting promising avenue for future targeted therapy investigations. Conclusion This review explores intricate interplay between cells, underscoring pivotal treatment. We summarise B‐cell‐related therapeutic targets, illustrating immense potential therapy. Our work lays theoretical foundation harnessing combination strategies Key points Chemotherapy can inhibit alter subset distributions functions, including factor secretion, receptor signalling, costimulation. modulate complex B‐cell–T‐cell interactions variable effects on immunity. Targeting surface markers signalling improves responses, blocks immune evasion inhibits growth. Critical knowledge gaps remain regarding TME, chemoresistance mechanisms, TLS biology, heterogeneity, spatial distributions, drug selection targets that studies should address.

Language: Английский

Citations

4
Friend or Foe: Prognostic and Immunotherapy Roles of BTLA in Colorectal Cancer DOI Creative Commons
Jingjing Song, Lihui Wu

Frontiers in Molecular Biosciences, Journal Year: 2020, Volume and Issue: 7

Published: July 21, 2020

B and T lymphocyte attenuator (BTLA) is a co-signaling protein belonging to the CD28 immunoglobulin superfamily. However, role of BTLA in prognosis immunotherapy colorectal cancer (CRC) remains unclear. We evaluated expression via Oncomine genome atlas (TCGA) database. research outcome among different patients by Kaplan-Meier curve. used Chi-Squared test Cox regression analysis identify potential risk factors. Besides, correlations between immune infiltration were investigated CIBERSORT. Various cohorts showed that was lower CRC compared corresponding normal tissue. Moreover, low correlated with poor overall survival TCGA Gene Expression Omnibus (GSE29623 GSE17536). Low associated less lymph node metastasis (p = 0.0123). In proportional hazards model, identified as favorable prognostic factor. Naive cells, memory CD8 CD4 resting follicular helper (Tfh) monocytes, natural killing (NK) M0 macrophages, M1 mast activated cells affected (all p < 0.01). Correlated markers functional enrichment revealed functioned cell receptor signaling pathway, NK cell-mediated cytotoxicity pathway. These analyses suggest factor for extended closely related Tfh CRC. summarize these results can be biomarker might contribute developing novel immunological treatment strategies.

Language: Английский

Citations

30